Duration of sweep gas off trial for weaning from venovenous extracorporeal membrane oxygenation.


Journal

Therapeutic advances in respiratory disease
ISSN: 1753-4666
Titre abrégé: Ther Adv Respir Dis
Pays: England
ID NLM: 101316317

Informations de publication

Date de publication:
Historique:
entrez: 19 11 2019
pubmed: 19 11 2019
medline: 27 6 2020
Statut: ppublish

Résumé

No data are available on the duration of time needed to assess the adequacy of lung function after stopping sweep gas for weaning of venovenous extracorporeal membrane oxygenation (ECMO). The objective of this study was to investigate changes in arterial blood gases (ABGs) during sweep gas off trials in patients receiving venovenous ECMO. Data on patients receiving venovenous ECMO, with a weaning trial at least once, were collected prospectively from January 2012 through December 2017. Serial changes in ABGs during sweep gas off trial and clinical outcomes after weaning from venovenous ECMO were evaluated. Over the study period, 192 sweep gas off trials occurred in 93 patients: 115 (60%) failed and 77 (40%) were successful. During the trial, significant changes in blood gases were observed within 1 h in all patients. When serial ABGs were compared according to trial off results, there were no significant differences in the pH, PaCO No change in blood gases was observed 2 h after stopping sweep gas in patients receiving venovenous ECMO. Based on our institutional experience, however, we suggest monitoring for 2 h or more after stopping sweep gas flow to assess if patients are ready for decannulation.

Sections du résumé

BACKGROUND
No data are available on the duration of time needed to assess the adequacy of lung function after stopping sweep gas for weaning of venovenous extracorporeal membrane oxygenation (ECMO). The objective of this study was to investigate changes in arterial blood gases (ABGs) during sweep gas off trials in patients receiving venovenous ECMO.
METHODS
Data on patients receiving venovenous ECMO, with a weaning trial at least once, were collected prospectively from January 2012 through December 2017. Serial changes in ABGs during sweep gas off trial and clinical outcomes after weaning from venovenous ECMO were evaluated.
RESULTS
Over the study period, 192 sweep gas off trials occurred in 93 patients: 115 (60%) failed and 77 (40%) were successful. During the trial, significant changes in blood gases were observed within 1 h in all patients. When serial ABGs were compared according to trial off results, there were no significant differences in the pH, PaCO
CONCLUSIONS
No change in blood gases was observed 2 h after stopping sweep gas in patients receiving venovenous ECMO. Based on our institutional experience, however, we suggest monitoring for 2 h or more after stopping sweep gas flow to assess if patients are ready for decannulation.

Identifiants

pubmed: 31736407
doi: 10.1177/1753466619888131
pmc: PMC6862773
doi:

Substances chimiques

Bicarbonates 0
Carbon Dioxide 142M471B3J
Oxygen S88TT14065

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1753466619888131

Références

Intensive Care Med. 2001 Apr;27(4):655-9
pubmed: 11403067
Chest. 2018 Jan;153(1):46-54
pubmed: 29037528
COPD. 2013 Aug;10(4):405-10
pubmed: 23537296
Ann Intensive Care. 2018 Feb 27;8(1):31
pubmed: 29484504
N Engl J Med. 2011 Nov 17;365(20):1905-14
pubmed: 22087681
Intensive Care Med. 2013 May;39(5):838-46
pubmed: 23291732
Respir Physiol. 1968 Sep;5(2):243-9
pubmed: 5683029
ASAIO J. 2017 Jan/Feb;63(1):60-67
pubmed: 27984321
Lancet Respir Med. 2014 Feb;2(2):154-64
pubmed: 24503270
Br J Anaesth. 1968 Oct;40(10):804
pubmed: 5698543
Heart Lung. 2010 Mar-Apr;39(2):147-52
pubmed: 20207275
Am J Respir Crit Care Med. 1995 Jul;152(1):148-52
pubmed: 7599814
Intensive Care Med. 2016 May;42(5):712-724
pubmed: 27007108
J Crit Care. 2013 Dec;28(6):998-1005
pubmed: 23954453

Auteurs

Soo Jin Na (SJ)

Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Hee Jung Choi (HJ)

Intensive Care Unit Nursing Department, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Chi Ryang Chung (CR)

Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Yang Hyun Cho (YH)

Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Kiick Sung (K)

Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Jeong Hoon Yang (JH)

Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Gee Young Suh (GY)

Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Joong Hyun Ahn (JH)

Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Keumhee C Carriere (KC)

Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, Alberta, Canada.

Kyeongman Jeon (K)

Department of Critical Care Medicine and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH